

7 June 2021

Cizzle Biotechnology Holdings Plc

(“Cizzle Biotechnology” or the “Company”)

2020 Annual Report and Notice of Annual General Meeting

Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of different forms of lung cancer, is pleased to announce the Company's Annual Report for the year ended 31 December 2020 and the Notice of Annual General Meeting (“AGM”) have now been published on the Company’s website at cizzlebiotechnology.com. A letter has been dispatched to all shareholders explaining the arrangements for the AGM together with hard copies of the 2020 Annual Report and Notice of AGM to any shareholders who have elected to receive them.

Annual General Meeting

The Annual General Meeting will be held at 11:00am on Tuesday 29th June 2021 at the offices of Goodman Derrick LLP, 10 St Bride Street, London, EC4A 4AD.

At the time of writing the current issues surrounding COVID-19 (coronavirus) and the current guidance from the UK Government is that indoor public gatherings are not permitted, which include attending a AGM. The health and safety of our shareholders and colleagues is always our utmost priority. At the time of writing it remains uncertain as to whether the guidance will be relaxed to allow physical attendance at the AGM. Therefore please note that if the public health guidance remains unchanged shareholders are advised not to attend the AGM in person and those that attend the venue may be denied entry. Therefore, we strongly encourage you to consider ensuring your vote is counted by submission of a proxy form in accordance with the notes set out within the Notice of Meeting. All shareholders are urged to appoint the Chairman of the meeting as their proxy, with voting instructions.

Although this outcome is undesirable, the directors of the Company believe that, in the current circumstances, there is no alternative to ensure the health, safety and security of attendees and to allow the business of the AGM to be transacted. We will continue to monitor the situation and the latest available public health guidance, and will provide updates in relation to our AGM on our website as and when necessary.

Should you wish to raise any questions ahead of the meeting please do so via email to the Company at cizzle@investor-focus.co.uk. We will endeavour to respond to all questions received by 5pm on Friday 23 June 2021 with any relevant Q&A being published on the Company website prior to the meeting.

Enquiries:

Cizzle Biotechnology Holdings plc

Via IFC Advisory

Allan Syms (Executive Chairman)

Allenby Capital Limited**+44(0) 20 33285656**

John Depasquale

Alex Brearley

Novum Securities Limited**+44(0) 20 7399 9400**

Colin Rowbury

Jon Bellis

IFC Advisory Limited**+44(0) 20 3934 6630**

Tim Metcalfe

Florence Chandler

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as C1Z1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is highly correlated with early stage lung cancer.